---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-006627"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T01:26:27.557818+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioCryst Q3 2023: ORLADEYO revenue $85.7M (+29.8% yoy); net loss narrows to $36.1M

## Summary
- Total Q3 2023 revenue $86.7M (+14.4% yoy), driven by ORLADEYO growth of $19.7M.
- Net loss $36.1M ($0.19/share) vs $42.5M ($0.23) in Q3 2022; operating cash use $16.5M (-43.9% yoy).
- Full-year 2023 ORLADEYO revenue guidance reaffirmed at no less than $320M; peak revenue target $1B.
- R&D expenses down 11% yoy to $46.9M due to program discontinuations; SG&A up 37% to $50.7M on ORLADEYO launch.
- Cash and investments $399.2M at Sep 30, 2023; debt interest expense rose on Pharmakon facility.

## SEC filing metadata
- accession: 0001171843-23-006627
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184323006627/0001171843-23-006627-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184323006627/f8k_110223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-006627
- JSON: https://secwatch.observer/filing/0001171843-23-006627.json
- Plain text: https://secwatch.observer/filing/0001171843-23-006627.txt

## Key facts
- Earnings Releases
  BIOCRYST PHARMACEUTICALS INC reported the third quarter ended September 30, 2023 results: revenue $86.7 million, net income $36.1 million, or $0.19 per share. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $86.7 million
  - Net income: $36.1 million, or $0.19 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: in the investors section of the company website at www.biocryst.com. Third Quarter 2023 Financial Results For the three months ended September 30, 2023, total revenues were $86.7 million, compared to $75.8 million in the third quarter of 2022 (+14.4 percent y-o-y). The increase was primarily due to an increase in ORLADEYO net revenue of $19.7 million, partially
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184323006627/0001171843-23-006627-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.